Latest ArticlesHost cell proteins (HCPs) are critical impurities that are difficult to remove completely during biopharmaceutical production. Their residual presence may compromise product safety, efficacy, and stability, while potentially inducing immune responses. Characterized by low abundance, HCPs demand exceptionally high detection sensitivity. Therefore, the precise quantification and rigorous control of HCPs are of paramount importance in biopharmaceutical quality assurance. This paper systematically reviews the current global regulatory status of HCPs, and analyzes the principles, application status, advantages and disadvantages of existing quality control technologies (including traditional detection methods and emerging technologies), providing a more comprehensive framework for HCPs control.Furthermore, it systematically addresses the major challenges encountered in HCPs detection, aiming to establish a theoretical foundation for future research and development of related technologies, as well as for drug regulation.
Heparin is widely used clinically as an anticoagulant drug, with its main source being porcine intestinal mucosa. Due to the impacts of the heparin sodium incident and the African swine fever incident, a supply shortage of porcine-derived heparin was once caused. Therefore, the FDA encourages manufacturers to increase the supply of heparin from other sources to mitigate the risk associated with relying on a single source. This paper focuses on bovine-derived heparin, analyzing differences from porcine-derived heparin in relative molecular weight, anticoagulant activity, and chemical structure (including monosaccharides, disaccharides, and tetrasaccharides). And the research progress on the preparation of low molecular weight heparin (LMWH) from bovine-derived heparin is also reviewed. Unfractionated bovine heparin can be directly applied to clinical practice, but due to its lower anticoagulant activity, it requires approximately twice the dose of porcine heparin to achieve the same effect. There are significant differences in structure and anticoagulant activity between bovine LMWH and porcine LMWH. Thus, if bovine LMWH is to be developed as a drug, it may need to be registered in accordance with the standards for new drugs.
Using 2-chlorotrityl chloride resin as the carrier, five natural amino acids (L-valine, L-tyrosine, L-glutamine, L-alanine, and L-alanine), one special amino acid (D-allo-threonine), and one chiral fatty side chain (5-hydroxytetradecanoic acid) as raw materials, the linear peptide was synthesized by Fmoc solid-phase synthesis with O- (benzotriazol-1-yl)-N, N, N', N'-tetramethyluronium hexafluorophosphate/1-hydroxybenzotriazole as the condensation system. 1- (3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride/4-dimethylaminopyridine was used as the cyclization system, followed by deprotection with trifluoroacetic acid and rapid column chromatographic purification to obtain the anti-tuberculosis drug, cordycommunin (1). The structure of 1 was confirmed by 1H NMR, 13C NMR and high resolution mass spectrometry (HRMS). After separation and purification, (R)- 1 [yield of 28.5% (calculated based on L-valine) with the purity of 98.2%] and (S)- 1 [yield of 23.7% (calculated based on L-valine) with the purity of 97.5%]were obtained. This method is simple and suitable for the synthesis of this series of cyclic peptides, providing a certain reference for the further research and application of highly anti-tuberculosis active cyclic peptides.
An improved synthetic process of tofacitinib citrate (1) was reported. 4-Chloro-7H-pyrrolo[2, 3-d]-pyrimidine (2) was protected with p-toluenesulfonyl, followed by substitution with (3R, 4R)-N, 4-dimethyl-1-benzyl-3-piperidinamine dihydrochloride, then deprotection, hydrogenation and salification to give N-methyl-N-[ (3R, 4R)-4-methylpiperidin-3-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine dihydrochloride (7). Subsequently, the condensation of 7 with cyanoacetic acid N-hydroxysuccinimide (9 , obtained by esterification of cyanacetic acid), followed by the saltification with citraric acid to obtain tofacitinib citrate 1 , with an overall yield of 47.7% (based on 2). The final product 1 showed a purity of over 99.9%, without signification impurities. The improved process shortened heterogeneous reaction times, moderated deprotection conditions, and improved quality of the key intermediates 7 and 9 . These modifications resulted in an elevated overall yield and delivered high-purity product, which is suitable for industrial-scale production.
The synthetic process of asciminib hydrochloride, a drug for treating chronic myeloid leukemia, was optimized. Methyl 5-bromo-6-chloronicotinate (2) was used as the starting material and condensed with (R)-pyrrolidin-3-ol (3) to generate methyl (R)-5-bromo-6- (3-hydroxypyrrolidin-1-yl) nicotinate (4). Compound 4 was subjected to Suzuki coupling reaction with 1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester to produce methyl 6-[ (R)-3-hydroxypyrrolidin-1-yl]-5-[1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl] nicotinate (6). Compound 6 was coupled with 4- (chlorodifluoromethoxy) aniline to produce (R)-5-[1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl]-N-[4- (chlorodifluoromethoxy)phenyl]-6- (3-hydroxypyrrolidin-1-yl) nicotinamide (8). Then compound 8 was deprotected to obtain free base of asciminib (1), while 1 was finally salified to obtain asciminib hydrochloride. Overall yield was 39.27% (based on 2) with purity of 99.89% and ee value of 99.88%. The optimized synthesis process of asciminib hydrochloride has mild conditions, controllable quality, and simple operation, which is suitable for industrial production.
The study systematically compared the performance differences between domestic and imported culture media in the cultivation of mesenchymal stem cells (MSCs). Three distinct culture systems were employed to culture MSCs, and key indicators including cell morphology, cell surface markers, differentiation potential, immunomodulatory capacity, karyotype analysis, cellular senescence, and soft agar colony formation were comprehensively evaluated to assess the safety, efficacy, and cell yield of MSCs in different culture systems. The results demonstrated that MSCs cultured in all three systems exhibited the typical spindle-shaped morphology, with cell surface markers conforming to international stem cell standards, and possessed osteogenic, adipogenic, and chondrogenic differentiation potential. The karyotype was normal, and soft agar colony formation assays confirmed the absence of tumorigenic risk. The results indicated that there was no significant difference between domestic and imported culture media. However, the domestic culture medium demonstrated certain advantages in some aspects: it had stronger cell proliferation ability and higher passage stability. In terms of immunomodulatory function, the domestic medium exhibited stronger inhibitory effects on T lymphocyte suppression and TNF-α. Cellular senescence assays showed a lower senescence rate in the domestic culture system. Additionally, when the domestic medium was used as a cryopreservation solution component, cells demonstrated faster recovery of viability post-thawing. This study provides scientific evidence to advance the domestic production of culture media in China, thereby enhancing the country’s independent innovation capabilities and international competitiveness in the field of stem cell research and application.
Dexmethylphenidate hydrochloride resin complexes (dMPH-DRC) and their sustained-release microcapsules (dMPH-CM) were prepared using ion exchange resin and immersion coating technology. The preparation processes of dMPH-DRC and dMPH-CM were optimized by single factor tests. The results showed that Amberlite® IRP69 (drug-to-resin mass ratio of 1∶1.5) exhibited the good drug loading performance. The prepared dMPH-DRC could achieve a drug loading capacity of (37.1±0.4)% and a drug utilization rate of (87.1±0.2)%. X-ray powder diffraction, polarizing light microscopy and differential scanning calorimetry analyses revealed that the drug-resin interaction was not merely physical adsorption. The sustained-release effect of dMPH-CM was primarily influenced by the coating material type and concentration, drug loading of the drug resin complex and preparation temperature. The optimized sustained-release microcapsules had a drug content of (36.75±0.34)%, an average particle size of (105±5)μm, a continuous and dense coating membrane, and a sustained-release duration of 12 hours. This simple preparation method provides a new approach for developing dexmethylphenidate sustained-release formulations.
The stability of Semen Cuscutae-Fructus Lycii (SC-FL) couplet medicines in artificial gastric juice and artificial intestinal fluid was investigated and its metabolism process in vitro was analyzed. A BEH C18 column (2.1 mm×50 mm, 1.7 μm) was used with acetonitrile-0.1% formic acid water as mobile phase in a gradient elution mode. SC-FL couplet medicines were co-incubated with in vitro artificial gastric juice, artificial intestinal fluid and liver homogenate, followed by qualitative analysis via UPLC-Q-TOF-MS. The results showed that the stability of SC-FL couplet medicines was good in artificial gastric juice but poor in artificial intestinal fluid. A total of 124 compounds were characterized and identified in the three types of samples, including 90 prototypical components, 23 metabolites, and 11 components that were both prototypical components and metabolites. The main components of SC-FL couplet medicines underwent phaseⅠmetabolic reactions, such as hydrolysis, reductive hydrogenation, and dehydroxylation, as well as phaseⅡ metabolic reactions, such as methylation, sulfation, and glucuronidation. The possible metabolic pathways were also speculated. This experiment can lay a foundation for further revealing the pharmacodynamic material basis and in vivo action process of SC-FL couplet medicines in the treatment of premature ovarian insufficiency.